Pharma BD Deal Intelligence

Exact Sciences Corporation / Genomic Health, Inc.

2019 · Acquisition/Merger · $2.8B · Complete

Positive — critic reaction at announcement

Worked — the deal delivered on its rationale

CALLED IT — OFF BY 11

Restore: 'for up to $100M'; 'Abbott agreed to acquire Exact Sciences for $105/share (~$21B equity, ~$23B enterprise value)' (per MDxHealth and Abbott sources on the record).

Key facts

Announced Jul 29, 2019
Closed Nov 08, 2019
Deal value $2.8B
Deal type Acquisition/Merger
Therapeutic area Oncology
Indications Breast cancer recurrence risk assessment, Prostate cancer genomic profiling, Colon cancer recurrence risk assessment
Key assets Oncotype DX Breast Recurrence Score, Oncotype DX Genomic Prostate Score, Oncotype DX Colon Recurrence Score, Genomic Health CLIA-certified laboratory (Redwood City), International commercial infrastructure (90+ countries), TAILORx clinical trial data supporting Oncotype DX
Mechanism Multigene RT-PCR expression assay, Genomic profiling for treatment decisions

Related deals — scored

Deal	Year	Value	Outcome
Exact Sciences Corporation / Genomic Health, Inc. (this deal)	2019	$2.8B	81
AstraZeneca PLC / Daiichi Sankyo Company, Limited	2019	$6.9B	100
Novartis AG / Endocyte, Inc.	2018	$2.1B	96
Astellas Pharma Inc. / Seagen Inc.	2009	$4.5B	95
Bristol-Myers Squibb Company / Medarex Inc.	2009	$2.4B	92
Servier / Agios Pharmaceuticals (oncology)	2020	$2.0B	91
Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc.	2020	$2.0B	91

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2019 deals · Oncology deals